The National Institute for Health and Care Excellence (NICE) has approved the use of a new bowel cancer treatment. Now, eligible patients in England and Wales can be given the drug Trifluridine/Tipiracil (Lonsurf), in combination with Bevacizumab (Avastin). This is great news for those with advanced bowel cancer who have exhausted other treatment options.
Here, we look at this new treatment option and what it means for patients.
Expanding treatment options for advanced bowel cancer
Bowel cancer, also known as colorectal cancer, is the fourth most common cancer in the UK. According to Bowel Cancer UK, it affects around 44,000 people each year. Advanced bowel cancer occurs when the disease has spread beyond the bowel to other parts of the body, making it more challenging to treat. Patients in this stage often face limited options after standard treatments have been used.
The approval of Lonsurf combined with Avastin provides a new avenue for patients who have already received two previous cancer treatment regimens. It is also suitable for those who have not been treated with Lonsurf before, or who are currently receiving Lonsurf as a standalone treatment.
Lonsurf is an oral chemotherapy drug that works by interfering with the growth of cancer cells, while Avastin is a targeted therapy that inhibits the formation of new blood vessels tumours need to grow. Together, they attack the cancer on multiple fronts, which can help slow down its rate of progression.
Clinical studies have shown that this combination of drugs can improve survival rates compared to using Lonsurf alone.
Collaborative efforts lead to approval
Getting the new bowel cancer treatment approved was a collaborative effort involving patient advocacy groups, healthcare professionals, and organisations like Bowel Cancer UK.
Making the treatment available on the NHS is a vital step forward for those with advanced bowel cancer who have limited treatment options. Access to this combination therapy offers hope of improved outcomes and precious additional time with loved ones.
The approval in England and Wales follows a similar decision by the Scottish Medicines Consortium (SMC) in August. This ensures that patients across the UK have the same access to this important treatment option.
Hope for Improved Quality of Life
Advanced bowel cancer can significantly impact a patient’s quality of life, causing symptoms like pain, fatigue, and digestive difficulties.
For many patients, the prospect of having another treatment option brings renewed optimism. It also helps doctors create personalised care plans that can better address the unique challenges each patient faces, helping them cope more effectively with the disease.
To learn more about bowel cancer treatments, schedule a consultation with Mr Stellakis today.
